Valuation : Protalix BioTherapeutics, Inc.

Market Cap 205M 176M 165M 151M 284M 19.56B 285M 1.96B 765M 9.87B 768M 752M 32.74B P/E 2026 *
13.4x
P/E 2027 * 46.2x
Enterprise Value 205M 176M 165M 151M 284M 19.56B 285M 1.96B 765M 9.87B 768M 752M 32.74B EV / Sales 2026 *
2.56x
EV / Sales 2027 * 3x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
1 day-2.68%
1 week+6.72%
Current month+7.17%
1 month+11.89%
3 months+20.38%
6 months-11.81%
Current year+41.11%
1 week 2.34
Extreme 2.34
2.65
1 month 2.17
Extreme 2.17
2.7
Current year 1.72
Extreme 1.72
3.19
1 year 1.52
Extreme 1.5201
3.19
3 years 0.82
Extreme 0.8214
3.19
5 years 0.7
Extreme 0.7
3.55
10 years 0.7
Extreme 0.7
15.15
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2019
Director of Finance/CFO 57 24/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member 73 01/07/2008
Director/Board Member 83 01/11/2014
Director/Board Member 59 30/06/2019
Date Insider Type Main position Quantity % Market Cap.
12/19/25 A Buy

Chief Executive Officer

56,000 0.0696%
11/18/25 A Sell

Director

168 0.0002%
9/3/25 A Free

Chief Operating Officer

75,000 0.0941%
Change 5-day change 1-year change 3-year change Capi.($)
-2.68%+6.72%+63.87%+30.26% 205M
-0.13%-6.44%+60.34%+112.06% 1,047B
+0.85%-0.81%+51.29%+63.13% 646B
-1.03%-3.58%+21.43%+73.10% 451B
-1.46%-4.50%+37.80%+37.41% 355B
-0.72%-2.89%+22.32%+36.62% 291B
-1.19%-2.21%+1.53%+10.79% 252B
-1.05%-1.57%+50.30%+66.55% 234B
+0.08%-1.78%-17.64%-54.36% 203B
-2.14%-0.30%+28.95%+86.27% 181B
Average -0.95%-1.44%+32.02%+46.18% 365.95B
Weighted average by Cap. -0.46%-3.46%+38.17%+65.00%

Financials

2026 *2027 *
Net sales 79.8M 68.76M 64.47M 58.85M 111M 7.63B 111M 765M 298M 3.85B 300M 293M 12.77B 68.19M 58.76M 55.1M 50.29M 94.75M 6.52B 95.05M 654M 255M 3.29B 256M 250M 10.91B
Net income 15.38M 13.25M 12.42M 11.34M 21.36M 1.47B 21.43M 147M 57.5M 742M 57.73M 56.47M 2.46B 4.46M 3.85M 3.61M 3.29M 6.2M 427M 6.22M 42.78M 16.69M 215M 16.76M 16.39M 714M
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
226
Date Price Change Volume
28/08/26 $2.540 -2.68% 490,228
27/08/26 $2.610 +5.24% 1,293,530
26/08/26 $2.480 +3.33% 1,023,782
25/08/26 $2.400 -0.41% 497,742
24/08/26 $2.410 +1.26% 409,933
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.540USD
Average target price
11.00USD
Spread / Average Target
+333.07%

Quarterly revenue - Rate of surprise